Melbourne spin-out Hatchtech receives AU$12.6m for head lice treatment.
Australia-based pharmaceutical company Hatchtech, a spin-out of the University of Melbourne, has received AU$12.6m ($11.9m) for a new head lice-killing product. The latest round was led by venture firm OneVentures, which was joined in participation by University of Melbourne, the Queensland Biotechnology Fund and spin-out focused venture fund Uniseed, and brings the company’s total venture…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
